Did anyone take a look at the Stimuvax data from ASCO? No position here, but wondering if anyone has any thoughts on Merck KG filing with EU based on that 800 patient subset. I was surprised to see oncologists tweeting that they were impressed by the subset data. What does KG have to lose by filing?